Law360, New York (March 7, 2014, 6:37 PM EST) -- A Massachusetts federal judge on Friday requested further briefing on whether he should reconsider portions of an order that granted victories to drugmakers Ranbaxy Inc. and Teva Pharmaceutical Industries Ltd. in a pay-for-delay class action involving the heartburn drug Nexium.
U.S. District Judge William G. Young denied a flurry of motions for reconsideration stemming from his multi-pronged Feb. 12 order, but laid out an expedited briefing schedule with regard to a pair of direct purchaser class plaintiffs' motions to give the Teva and Ranbaxy summary judgment decisions a second look.
“These two motions require more thorough analysis,” Judge Young said in...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!